Lynk’s allosteric TYK2 inhibitor LNK-01006 gains IND clearance

Dec. 3, 2025

Lynk Pharmaceuticals Co. Ltd. has received IND clearance from the FDA for LNK-01006, an allosteric TYK2 inhibitor with potential to treat neurodegenerative diseases.

BioWorld Science Regulatory Neurology/psychiatric FDA IND

Today's news in brief

BioWorld

BioWorld briefs for Jan 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 6, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...